8-K - Zenas BioPharma, Inc. | StockGist

Current Report Details

Event Type

Financial Results+3 More

Disclosure

Mandatory

Variant

8-K

Items Reported

2.02

. Results of Operations and Financial Condition Zenas BioPharma, Inc. (the “Company”) reports that it had a preliminary unaudited amount of cash, cash equivalen

Financial Results

$360.5M

7.01

of this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchang

Regulation Fd

8.01

. Other Events On January 5, 2026, the Company announced positive results from the INDIGO trial. The INDIGO trial enrolled a total of 194 patients, randomized t

Other Event

$300.0M$75.0M$75.0M

9.01

Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated January 5, 2026 104 Cover Page Interactive Data File (embedded

Exhibits Only

Source Document

Exhibits (2)

8-K

FORM 8-K

99.1

EXHIBIT 99.1